Aadi Bioscience, Inc. (AADI) Expected to Beat Earnings Estimates: Should You Buy?

Core Viewpoint - Aadi Bioscience, Inc. is anticipated to report a year-over-year increase in earnings driven by higher revenues for the quarter ending December 2024, with the actual results being crucial for its near-term stock price movement [1][2]. Financial Expectations - The consensus estimate indicates a quarterly loss of $0.25 per share, reflecting a year-over-year improvement of +58.3$7.6 million, marking a 20.1% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the past 30 days, indicating that analysts have not significantly altered their initial projections during this period [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model shows that the Most Accurate Estimate for Aadi Bioscience is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +9.21%, suggesting a bullish outlook from analysts [10]. Zacks Rank - Aadi Bioscience holds a Zacks Rank of 2, which, combined with the positive Earnings ESP, indicates a strong likelihood of beating the consensus EPS estimate [11]. Historical Performance - In the last reported quarter, Aadi Bioscience met the expected loss of $0.46 per share, resulting in no surprise. Over the past four quarters, the company has exceeded consensus EPS estimates twice [12][13]. Conclusion - Aadi Bioscience is positioned as a compelling candidate for an earnings beat, although investors should consider additional factors beyond earnings expectations when making investment decisions [16].